Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin
- PMID: 12408998
- DOI: 10.1016/s0014-2999(02)02391-9
Antagonists of platelet fibrinogen receptor are less effective in carriers of Pl(A2) polymorphism of beta(3) integrin
Abstract
The polymorphism Leu(33)-->Pro (platelet-specific antigen; Pl(A1/A2)) of platelet GPIIIa is a potential risk factor for arterial thrombosis. However, its influence on platelet function remains controversial and little is known about its impact on platelet sensitivity to GPIIb-IIIa antagonists. Our objective was to compare the effectiveness of various GPIIb-IIIa antagonists in Pl(A2)(+) and Pl(A2)(-) carriers. Platelet aggregation was monitored in healthy donors including Pl(A2)(-) (N=31) and Pl(A2)(+) subjects (N=27; 23 Pl(A1/A2), 4 Pl(A2)/(A2)) using the impedance and turbidimetric aggregation techniques. We evaluated the inhibition of ADP- and collagen-induced aggregation by disintegrins, kistrin and echistatin, and the low-molecular-weight blockers, GR144053F ((4-[4-[4-(aminoiminomethyl]-1-piperazinyl]-1-piperidineacetic acid, hydrochloride trihydrate) and eptifibatide (N(6)-(aminoiminomethyl)-N(2)-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-propyl-L-cysteinamide, cyclic (1-->6)-disulfide). Kistrin (10-30 nmol/l) inhibited ADP- and collagen-induced aggregation stronger in Pl(A2)(-) donors than in Pl(A2)(+) donors; there was a significant difference between 50% inhibitory concentrations (IC(50)). The same tendency occurred with moderate concentrations of eptifibatide (40-100 nmol/l) and also at low concentrations of GR144053F (5-10 nmol/l) and high concentrations of echistatin (80-150 nmol/l), although in the case of the two latter inhibitors, the estimated IC(50) values were not significantly different. In conclusion, GPIIb-IIIa blockers representing various classes are less effective inhibitors of platelet aggregation in Pl(A2)(+) carriers; however, the effect of the genotype is both agonist- and antagonist-dependent.
Similar articles
-
The impact of genetic variation in the region of the GPIIIa gene, on Pl expression bias and GPIIb/IIIa receptor density in platelets.Br J Haematol. 2006 Feb;132(4):494-502. doi: 10.1111/j.1365-2141.2005.05897.x. Br J Haematol. 2006. PMID: 16412022
-
Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice.Am J Pharmacogenomics. 2005;5(2):93-9. doi: 10.2165/00129785-200505020-00002. Am J Pharmacogenomics. 2005. PMID: 15813672 Review.
-
Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa).Br J Haematol. 2000 Sep;110(4):911-8. doi: 10.1046/j.1365-2141.2000.02300.x. Br J Haematol. 2000. PMID: 11054082
-
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.Circulation. 2000 Mar 7;101(9):1013-8. doi: 10.1161/01.cir.101.9.1013. Circulation. 2000. PMID: 10704169
-
[Anti-integrins--new platelet function inhibitors for therapy and prevention of acute coronary syndrome].Wien Klin Wochenschr. 1999 Feb 12;111(3):90-7. Wien Klin Wochenschr. 1999. PMID: 10093890 Review. German.
Cited by
-
The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.J Thromb Thrombolysis. 2005 Aug;20(1):57-63. doi: 10.1007/s11239-005-2912-2. J Thromb Thrombolysis. 2005. PMID: 16133898
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources